Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002324 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
A Phase 2 study of HIV Infections, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 18
- Study locations
NCT00002324 is a Phase 2 study of HIV Infections that has completed, run by Boehringer Ingelheim. The registered enrollment target is 250 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT00002324, a Phase 2 study of HIV Infections, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 18
- Study locations
Study Summary
PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment. To evaluate the safety and tolerance of nevirapine alone or in combination with AZT. SECONDARY: To compare the effects of the various treatment combinations on virologic and immunologic markers.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Nevirapine
Study Locations (18)
California
- UCSD Treatment Ctr - San Diego
- Saint Francis Mem Hosp - San Francisco
Florida
- Community Research Initiative of South Florida - Coral Gables
- Goodgame Med Group - Maitland
Texas
- Nelson-Tebedo Community Clinic - Dallas
- Houston Clinical Research Network - Houston
Virginia
- Infectious Disease Physicians Inc - Annandale
- Richmond AIDS Consortium - Richmond
Delaware
- Wilmington Hosp - Wilmington
Kansas
- Univ of Kansas School of Medicine - Wichita
Kentucky
- Chandler Med Ctr - Lexington
Missouri
- Kansas City AIDS Research Consortium - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002324
The ClinicalTrials.gov registry entry for NCT00002324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (44% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002324 reports 18 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00002324 about?
NCT00002324 is a clinical study titled "The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease". PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment. To evaluate the safety and tolerance of nevirapine alone or in combination with AZT. SECONDARY: To compare the effects of t...
What is the current status of trial NCT00002324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants.
What conditions does trial NCT00002324 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002324?
The interventions under investigation include: Zidovudine (DRUG), Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00002324?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002324 being conducted?
This trial has 18 study locations across California, Delaware, Florida, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.